Nine out of 10 elderly dementia sufferers become less agitated after marijuana treatment, study finds

A groundbreaking clinical trial has revealed that a medical cannabis oil capsule containing purified THC and CBD significantly reduces agitation in elderly patients with advanced dementia. Presented at the Alzheimer’s Association International Conference, the LiBBY trial found that nearly 90% of participants experienced overall improvement, a response rate rarely seen in dementia-related clinical research. These findings are significant for the cannabis sector as they provide clinical evidence for the therapeutic potential of cannabinoids in treating complex neurological symptoms that traditional medications often fail to manage.

The LiBBY trial (Life’s end Benefits of cannaBidiol and tetrahYdrocannabinol) involved 120 participants with Alzheimer’s disease or other forms of dementia who were either in or eligible for hospice care. Led by Dr. Jacobo Mintzer of the University of South Carolina and Brigid Reynolds of Georgetown University, the study utilized a rapid-acting digestible oil suspension containing a combination of purified THC and CBD. After 12 weeks, researchers observed that nearly 90% of the subjects showed positive responses, with those receiving the medication experiencing a 6.27-point reduction in mean agitation scores after just two weeks.

This clinical success marks a potential shift in the treatment of dementia-related agitation, which is characterized by restlessness, aggression, and emotional distress. Historically, caregivers have relied on medications like morphine, Valium, and Haldol, which the study notes have limited effectiveness and can cause adverse side effects. Dr. Mintzer emphasized that the level of response seen in this trial was unprecedented, offering hope for a new standard of care that improves the quality of life for both patients and their families.

Despite the promising results, the research team issued a cautionary note regarding the broader cannabis market, distinguishing their medical-grade formulation from commercially available products. Brigid Reynolds warned that over-the-counter THC and CBD products vary widely in composition and quality, potentially making them ineffective or harmful compared to the carefully manufactured oil used in the supervised trial. For the cannabis and hemp industry, this highlights a growing need for standardized, pharmaceutical-grade cannabinoid products as the medical community seeks reliable alternatives for geriatric care.